-0.005 (-3.636%)Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Mqv
Very Weak
Garp
Very Weak
Mqv Small
Neutral
Value
Consensus
Price
Neutral
Earnings
Weak
Earnings
Neutral
Dividends
Very Weak
Capital Efficiency
Very Weak
Balance Sheet
Very Weak
Website
Fusion Antibodies Plc
Telephone
44.28.9043.2800
Address
1 Springbank Road, Springbank Industrial Estate, Dunmurry, Belfast BT17 0QL
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.06 - 0.21
Trade Value (12mth)
US$40,109.00
1 week
-11.67%
1 month
-5.36%
YTD
-1.85%
1 year
93.43%
All time high
2.50
EPS 3 yr Growth
-82.00%
EBITDA Margin
-84.60%
Operating Cashflow
-£2m
Free Cash Flow Return
0.00%
ROIC
0.00%
Interest Coverage
0.00
Quick Ratio
0.00
Shares Outstanding (Fully Diluted)
113m
HALO Sector
Healthcare
Next Company Report Date
03-Sep-26
Next Ex Dividend Date
N/A
Next Dividend Pay Date
N/A
Reporting Currency
GBP
Short Sell (% of issue)
0.00
| Date | Announcements |
| 12 May 26 | |
| 11 May 26 | |
| 05 May 26 | |
| 30 March 26 | |
| 17 February 26 |
Historical data
Forecast data
| GBP | 2021 | 2022 | 2023 | 2024 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |||
| Per Share, Growth & Valuations | |||||||||||||
EPS (Basic) | £ |  | | | | -0.04 | -0.02 | -0.02 | | | | ||
EPS (Fully Diluted) | £ | | | | | -0.04 | -0.02 | N/A | | | | ||
Growth | % | | | | | 59.8 | 55.4 | -0.6 | | | | ||
PE | X | | | | | N/A | N/A | N/A | | | | ||
EV/EBITDA | X | | | | | N/A | N/A | N/A | | | | ||
Ex Dividend Date (est.)
DIV Yield
Franking Level
DPSg
Quality Yield
Falling Divs over next 2
Consensus Score
Recommendation
EPS 1 month Change
Quality Yield
Falling Divs over next 2
